Phase 1 data demonstrate that SRP-001 exhibits an exceptionally strong safety and robust pharmacokinetic profile and is well-tolerated Well-designed Phase 2 trials set to show statistical significance compared to placebo and positive control NEW ORLEANS, Jan. 2, 2024 /PRNewswire/ — South…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.